Michael Zile
Brigham and Women's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michael Zile.
Journal of the American College of Cardiology | 2016
Thomas A. Gaziano; Gregg Fonarow; Brian Claggett; Milton Packer; Michael Zile; Karl Swedberg; Jean L. Rouleau; John J.V. McMurray; Wing Chan; Stuart Turner; Celine Deschaseaux; Scott D. Solomon
The angiotensin receptor neprilysin inhibitor LCZ696 (sacubitril/valsartan) reduced all-cause death and HF hospitalizations compared to enalapril. We assessed the cost-effectiveness of LCZ696 relative to enalapril in the US. Using PARADIGM-HF trial data, a two-state Markov model was developed for
Journal of the American College of Cardiology | 2016
Scott D. Solomon; John J.V. McMurray; Akshay S. Desai; Michael Zile; Karl Swedberg; Victor Shi; Martin Lefkowitz; Ricardo Rocha
Clinical instability has been suggested as a potential criteria to determine which patients should be considered for ACE/ARB replacement therapy with LCZ696 (sacubitril/valsartan). We identified patients who were clinically stable, defined as NYHA Class II with no history of prior heart failure
Journal of the American College of Cardiology | 2017
Jelena P. Seferovic; Sara B. Seidelmann; Brian Clagett; Milton Packer; Michael Zile; Jean L. Rouleau; Karl Swedberg; Martin Lefkowitz; Victor Shi; Akshay S. Desai; John J.V. McMurray; Scott D. Solomon
Background: Type 2 diabetes (T2DM) is an independent risk factor for heart failure progression. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, improves morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF) and was shown to improve
Journal of the American College of Cardiology | 2013
Angela B. S. Santos; Elisabeth Kraigher-Krainer; Michael Zile; Burkert Pieske; Adriaan Voors; John J.V. McMurray; Milton Packer; Toni Bransford; Marty Lefkowitz; Amil M. Shah; Scott D. Solomon
Mechanical dyssynchrony has been proposed to play a pathophysiologic role in heart failure with preserved ejection fraction (HFpEF). We quantified LV systolic and diastolic function and dyssynchrony in 210 HFpEF patients with NYHA class II-IV symptoms, EF >45%, and NT-proBNP levels >400 pg/mL
Journal of the American College of Cardiology | 2012
Imran Uraizee; Susan Cheng; Chung-Lieh Hung; Anil Verma; James Thomas; Michael Zile; Gerard P. Aurigemma; Scott D. Solomon
Elevated Nt-pro-BNP levels are associated with increased risk for heart failure in asymptomatic individuals. The degree to which increased BNP is related to subclinical cardiac dysfunction in hypertension (HTN) is unclear. We studied a subset of 330 patients (51p women, aged 61±9
Journal of the American College of Cardiology | 2018
Tor Biering-Sørensen; Amil M. Shah; Brian Claggett; Michael Zile; Burkert Pieske; Elisabeth Pieske-Kraigher; Adriaan Voors; Victor Shi; Martin Lefkowitz; Milton Packer; John J.V. McMurray; Scott D. Solomon
Journal of the American College of Cardiology | 2018
Muthiah Vaduganathan; Brian Claggett; Milton Packer; John J.V. McMurray; Jean L. Rouleau; Michael Zile; Karl Swedberg; Scott D. Solomon
European Heart Journal | 2017
Michael Zile; Eileen O'Meara; Margaret F. Prescott; Brian Claggett; Scott D. Solomon; Karl Swedberg; Milton Packer; John. J. V. McMurray; Victor Shi; M. Lefkowitz; Jean-Lucien Rouleau
European Heart Journal | 2017
Michael Zile; Eileen O'Meara; Brian Claggett; Margaret F. Prescott; Scott D. Solomon; Karl Swedberg; Milton Packer; John. J. V. McMurray; Victor Shi; M. Lefkowitz; Jean-Lucien Rouleau
Journal of the American College of Cardiology | 2016
Wilson Nadruz Junior; Brian Claggett; John J.V. McMurray; Milton Packer; Michael Zile; Jean L. Rouleau; Akshay S. Desai; Karl Swedberg; Martin Lefkowitz; Victor Shi; Margaret Prescott; Scott D. Solomon
